Business

Italfarmaco has announced that it will pay Neupharma "a total sum up to double digits in USD millions, excluding royalties" for an exclusive option to acquire global development and commercialization rights to inhaled teicoplanin for the treatment methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The inhaled teicoplanin … [Read more...] about Italfarmaco to develop inhaled teicoplanin for the treatment of MRSA infections in CF patients

A spokesperson for Novartis has confirmed to OINDPnews that Mylan exercised an option to acquire a San Carlos, CA, USA manufacturing facility for TOBI inhaled tobramycin products in May 2019 and is expected to acquire the site assets in September 2019. Mylan paid approximately $463 million to Novartis for worldwide rights to TOBI Podhaler DPI and TOBI inhalation … [Read more...] about Mylan to acquire TOBI manufacturing facility

Italian pharmaceutical company Zambon announced that it has paid €140 million up front for Breath Therapeutics, which is developing L‑CsA‑i inhaled liposomal Cyclosporine A for the treatment of bronchiolitis obliterans syndrome (BOS). The deal includes regulatory and sales milestones that could bring the total up to €500 million. Breath Therapeutics is a spin off … [Read more...] about Zambon acquires Breath Therapeutics

BlueWillow Biologics announced that it has been issued US patent No. 10,206,996, titled "Herpes simplex virus nanoemulsion vaccine," covering an intranasal herpes simplex virus (HSV) vaccine based on its NanoVax adjuvant platform. The company is developing the vaccine to protect against HSV-1 and HSV-2, which can cause genital herpes. According to the company, … [Read more...] about BlueWillow Biologics gets US patent for intranasal HSV vaccine

In a business update, Vectura Group said that the company is focusing its R&D strategy on partnerships for development of its inhaled drug candidates. The company also said that it is considering how to structure a proposed £50 million return of capital which it expects to begin this year as a result of its "reducing R&D risk profile, future cash generation … [Read more...] about Vectura focused on securing partners for development of inhaled drugs

Inhaled drug developer MannKind Corporation announced that the company has expanded its capacity for commercial manufacturing of highly potent dry powder formulations at its facility in Danbury, Connecticut, USA. The new manufacturing suite includes bulk powder formulation and filling for high potency powders such as epinephrine, the company said. According to … [Read more...] about MannKind adds high potency DPI formulation manufacturing capacity

Liquidia Technologies has announced amendments to its 2012 collaboration agreement with GlaxoSmithKline that gave GSK the rights to develop inhaled dry powder formulations based on Liquidia's PRINT particle manufacturing technology. Under the terms of the amended agreement, Liquidia gets development and commercialization rights to three PRINT-based inhalation … [Read more...] about Liquidia to develop additional inhaled drugs

Insmed has announced that it raised ~$25.6 million in net proceeds through the sale of additional shares after a public offering earlier this year netted approximately $235.5 million. The underwriters of that offering had a 30-day option to purchase up to 1,042,307 additional shares of common stock from the company and up to 400,000 shares of common stock from … [Read more...] about Insmed raises additional $25.6 million in public offering